CA3227596A1 - Methods for treating nervous system disorders with antipurinergic agents - Google Patents

Methods for treating nervous system disorders with antipurinergic agents Download PDF

Info

Publication number
CA3227596A1
CA3227596A1 CA3227596A CA3227596A CA3227596A1 CA 3227596 A1 CA3227596 A1 CA 3227596A1 CA 3227596 A CA3227596 A CA 3227596A CA 3227596 A CA3227596 A CA 3227596A CA 3227596 A1 CA3227596 A1 CA 3227596A1
Authority
CA
Canada
Prior art keywords
antipurinergic
agent
dosing regimen
receptor
loading
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3227596A
Other languages
English (en)
French (fr)
Inventor
Zachary ROME
Michael Derby
David W. Hough
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PaxMedica Inc
Original Assignee
PaxMedica Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PaxMedica Inc filed Critical PaxMedica Inc
Publication of CA3227596A1 publication Critical patent/CA3227596A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3227596A 2021-08-23 2022-08-22 Methods for treating nervous system disorders with antipurinergic agents Pending CA3227596A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163236155P 2021-08-23 2021-08-23
US63/236,155 2021-08-23
PCT/US2022/041050 WO2023027994A1 (en) 2021-08-23 2022-08-22 Methods for treating nervous system disorders with antipurinergic agents

Publications (1)

Publication Number Publication Date
CA3227596A1 true CA3227596A1 (en) 2023-03-02

Family

ID=85321996

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3227596A Pending CA3227596A1 (en) 2021-08-23 2022-08-22 Methods for treating nervous system disorders with antipurinergic agents

Country Status (8)

Country Link
US (1) US20240277641A1 (enExample)
EP (1) EP4366828A1 (enExample)
JP (1) JP2024532288A (enExample)
CN (1) CN118103072A (enExample)
AU (1) AU2022332894A1 (enExample)
CA (1) CA3227596A1 (enExample)
IL (1) IL310559A (enExample)
WO (1) WO2023027994A1 (enExample)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04009310A (es) * 2002-03-26 2005-01-25 Eastern Virginia Med School Suramin y derivados del mismo como microbicidas y contraceptivos.
EP2770985A4 (en) * 2011-10-25 2015-01-21 U S Phytotherapy Inc ARTEMISININE AND BERBERINE COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF
IL282156B (en) * 2014-07-29 2022-07-01 Shenzhen Hightide Biopharmaceutical Ltd Berberine salts, ursodeoxycholic salts and combinations, methods of preparation and application thereof
CN118697876A (zh) * 2017-02-09 2024-09-27 完美日光有限公司 用于自闭症谱系障碍药物治疗的方法
JP7749169B2 (ja) * 2019-06-07 2025-10-06 クヴァトリス セラピューティクス， インコーポレイテッド 中枢神経系障害を処置するための組成物および方法
IL302224A (en) * 2020-10-22 2023-06-01 Paxmedica Inc Administration of anti-purinergic preparations for the treatment of disorders of the nervous system

Also Published As

Publication number Publication date
AU2022332894A1 (en) 2024-02-29
JP2024532288A (ja) 2024-09-05
IL310559A (en) 2024-03-01
WO2023027994A1 (en) 2023-03-02
EP4366828A1 (en) 2024-05-15
CN118103072A (zh) 2024-05-28
US20240277641A1 (en) 2024-08-22

Similar Documents

Publication Publication Date Title
JP2021508670A (ja) 疾患の処置のための鼻腔内エピネフリン製剤及び方法
CN114340597B (zh) 用于治疗中枢神经系统障碍的组合物和方法
JP2003176240A (ja) ニコチン性アセチルコリン受容体作用薬により関節の潤滑を高める方法
US20230390223A1 (en) Administration of antipurinergic compositions for treating nervous system disorders
US20230390226A1 (en) Intranasal administration of suramin for treating nervous system disorders
US20240277641A1 (en) Methods for treating nervous system disorders with antipurinergic agents
US20220202816A1 (en) Compositions and methods for treating lung injuries associated with sars-cov-2 infections
BRPI0616144A2 (pt) composiÇço terapÊutica, uso de uma composiÇço terapÊutica,composiÇço farmacÊutica, e, uma primeira composiÇço terapÊutica compreendendo um composto s-nitrosotiol e uma segunda composiÇço terapÊutica compreendendo um segundo composto que nço o composto s-nitrosotiol
GB2607584A (en) Composition and method of treatment
US20250262173A1 (en) Intranasal epinephrine formulations and methods of use
US20250161255A1 (en) New therapy and prevention for suppressing aging-related disorders including sarcopenia
JP2002363076A (ja) フマギロール誘導体を用いる腫瘍の治療方法
HK40073161B (zh) 用於治疗中枢神经系统障碍的组合物和方法
WO2025084921A1 (es) Desarrollo de formulaciones para el manejo y tratamiento antiviral, inmunomodulador y antiinflamatorio de la infección por el nuevo sars-cov2 y la enfermedad desarrollada el covid-19 y sus variantes, formulada a partir de la sal del ácido glicirricínico y sus derivados de su estructura química
CN118164978A (zh) 二氢喹嗪酮羧酸类化合物及其作为trpv4通道抑制剂的应用
HK40073161A (en) Compositions and methods for treating central nervous system disorders

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250307

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250307

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250307

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250822

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250822

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251027